Drug Type Gene therapy |
Synonyms ACRX-100, GP-51801, GP51801 + [4] |
Target |
Action modulators, inducers, inhibitors, + [1] |
Mechanism SDF-1 modulators(C-X-C motif chemokine ligand 12 modulators), Angiogenesis inducers, Apoptosis inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Brain Injuries, Traumatic | Phase 2 | United States | 01 Nov 2015 | |
Visible Lesion | Phase 2 | United States | 01 Nov 2015 | |
Heart Failure | Phase 2 | United States | 01 Jul 2012 | |
Chronic Limb-Threatening Ischemia | Phase 2 | United States | 01 Mar 2012 | |
Chronic Limb-Threatening Ischemia | Phase 2 | India | 01 Mar 2012 | |
Perioperative ischaemia | Phase 2 | United States | 01 Mar 2012 | |
Perioperative ischaemia | Phase 2 | India | 01 Mar 2012 | |
Peripheral ischaemia | Phase 2 | India | 12 Jan 2012 | |
Peripheral Arterial Disease | Phase 2 | - | - | |
Peripheral Arterial Disease | Phase 2 | - | - |
Phase 2 | 109 | Placebo | rvgjwqxcpx(yjscrwhkug) = ejumkeexah eaavmhwuml (awaydrptwk ) | Negative | 01 Jun 2019 | ||
JVS-100 8 mg | rvgjwqxcpx(yjscrwhkug) = ztlhzesxjg eaavmhwuml (awaydrptwk ) |